Posted by Michael Wonder on 19 Jun 2026
Corcept resubmits new drug application for relacorilant as a treatment for patients with Cushing’s syndrome
17 June 2026 - Corcept Therapeutics today announced it has resubmitted its new drug application to the US FDA for relacorilant as a treatment for patients with Cushing’s syndrome.
As requested by the FDA, the resubmission includes additional analyses of data included in the original new drug application submission.
